Alladapt Immunotherapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Alladapt Immunotherapeutics's estimated annual revenue is currently $3.2M per year.
- Alladapt Immunotherapeutics's estimated revenue per employee is $77,500
Employee Data
- Alladapt Immunotherapeutics has 41 Employees.
- Alladapt Immunotherapeutics grew their employee count by -38% last year.
Alladapt Immunotherapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Head Clinical Quality Assurance (Sr. Director) | Reveal Email/Phone |
2 | SVP, Development Operations | Reveal Email/Phone |
3 | VP, Information Technology & Business Operations | Reveal Email/Phone |
4 | Director, Pharmaceutical Engineering | Reveal Email/Phone |
5 | Director CMC | Reveal Email/Phone |
6 | Director, FP&A | Reveal Email/Phone |
7 | Senior Medical Director, Medical Development | Reveal Email/Phone |
8 | Director, Clinical Data Management | Reveal Email/Phone |
9 | Senior Scientist | Reveal Email/Phone |
Alladapt Immunotherapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is Alladapt Immunotherapeutics?
A biopharmaceutical company developing prescription therapies for unmet needs in the field of Food Allergy
keywords:N/AN/A
Total Funding
41
Number of Employees
$3.2M
Revenue (est)
-38%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8.9M | 41 | 3% | N/A |
#2 | $8.9M | 41 | -61% | N/A |
#3 | $5.7M | 41 | 5% | N/A |
#4 | $6.7M | 41 | 3% | N/A |
#5 | $4.8M | 41 | 86% | N/A |